Biodexa Pharmaceuticals (BDRX) Change in Account Payables (2013 - 2022)

Biodexa Pharmaceuticals has reported Change in Account Payables for 4 years, with the latest figure at $1.1 million in Q3 2021.

• Quarterly Change in Account Payables rose 1201.69% year-over-year to $1.1 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at -$1.2 million, down 141.89% from the prior year.
• Change in Account Payables grew to $1.1 million in Q3 2021 per BDRX's latest filing, from $91111.1 in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.1 million in Q3 2021 and troughed at -$55286.2 in Q4 2019.
• A 3-year average of $313439.0 and a median of $89000.7 in 2020 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2020 and 2021: Change in Account Payables jumped 264.8% in 2020, then soared 1201.69% in 2021.
• Over 3 years, Change in Account Payables stood at -$55286.2 in 2019, then surged by 264.8% to $91111.1 in 2020, then soared by 1141.39% to $1.1 million in 2021.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.1 million, $91111.1, and $86890.3 for Q3 2021, Q4 2020, and Q3 2020 respectively.